Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

Pamrevlumab in idiopathic pulmonary fibrosis.

Wells AU.

Lancet Respir Med. 2019 Sep 27. pii: S2213-2600(19)30339-X. doi: 10.1016/S2213-2600(19)30339-X. [Epub ahead of print] No abstract available.

PMID:
31575507
2.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Sep 29. doi: 10.1056/NEJMoa1908681. [Epub ahead of print]

PMID:
31566307
3.

Pleuroparenchymal Fibroelastosis: A Review of Clinical, Radiological and Pathological Characteristics.

Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, Wells AU.

Ann Am Thorac Soc. 2019 Aug 19. doi: 10.1513/AnnalsATS.201902-181CME. [Epub ahead of print]

PMID:
31425665
4.

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.

Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU.

Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12.

PMID:
31416769
5.

Evaluation of inter-observer variation for computed tomography identification of childhood interstitial lung disease.

Jacob J, Owens CM, Brody AS, Semple T, Watson TA, Calder A, Garcia-Peña P, Toma P, Devaraj A, Walton H, Moreno-Galdó A, Aurora P, Rice A, Vece TJ, Cunningham S, Altmann A, Wells AU, Nicholson AG, Bush A.

ERJ Open Res. 2019 Jul 29;5(3). pii: 00100-2019. doi: 10.1183/23120541.00100-2019. eCollection 2019 Jul.

6.

Treatment of cardiac sarcoidosis.

Kouranos V, Wells AU, Sharma R.

Curr Opin Pulm Med. 2019 Sep;25(5):519-525. doi: 10.1097/MCP.0000000000000611.

PMID:
31365386
7.

Treatment of cardiac sarcoidosis.

Kouranos V, Wells AU, Sharma R.

Curr Opin Pulm Med. 2019 Jul 24. doi: 10.1097/MCP.0000000000000611. [Epub ahead of print]

PMID:
31343492
8.

Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Jun 26. doi: 10.1164/rccm.201903-0493OC. [Epub ahead of print]

9.

Diagnosing complications and co-morbidities of fibrotic interstitial lung disease.

Margaritopoulos GA, Kokosi MA, Wells AU.

Expert Rev Respir Med. 2019 Jul;13(7):645-658. doi: 10.1080/17476348.2019.1632196. Epub 2019 Jul 5.

PMID:
31215263
10.

Novel exploratory data in interstitial lung disease.

Wells AU.

Respirology. 2019 Aug;24(8):718-719. doi: 10.1111/resp.13621. Epub 2019 Jun 18. No abstract available.

11.

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis.

Jacob J, Bartholmai BJ, van Moorsel CHM, Rajagopalan S, Devaraj A, van Es HW, Moua T, van Beek FT, Clay R, Veltkamp M, Kokosi M, de Lauretis A, Judge EP, Jacob TM, Peikert T, Karwoski R, Maldonado F, Renzoni E, Maher TM, Altmann A, Wells AU.

Eur Respir J. 2019 Sep 30;54(3). pii: 1802341. doi: 10.1183/13993003.02341-2018. Print 2019 Sep. No abstract available.

PMID:
31196945
12.

Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis.

Barnett J, Molyneaux PL, Rawal B, Abdullah R, Hare SS, Vancheeswaran R, Desai SR, Maher TM, Wells AU, Devaraj A.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900531. doi: 10.1183/13993003.00531-2019. Print 2019 Jul.

PMID:
31164428
13.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation.

Stock CJW, Michaeloudes C, Leoni P, Durham AL, Mumby S, Wells AU, Chung KF, Adcock IM, Renzoni EA, Lindahl GE.

Biomed Res Int. 2019 Apr 18;2019:1484736. doi: 10.1155/2019/1484736. eCollection 2019.

14.

Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path.

Renzoni EA, Wells AU.

Respirology. 2019 Jul;24(7):620-621. doi: 10.1111/resp.13584. Epub 2019 May 15. No abstract available.

15.

Visual and Automated CT Measurements of Lung Volume Loss in Idiopathic Pulmonary Fibrosis.

Robbie H, Wells AU, Jacob J, Walsh SLF, Nair A, Srikanthan A, Tazoniero P, Devaraj A.

AJR Am J Roentgenol. 2019 Aug;213(2):318-324. doi: 10.2214/AJR.18.20884. Epub 2019 May 7.

PMID:
31063425
16.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

17.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
18.

Pulmonary fibrosis: "idiopathic" is not "cryptogenic".

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900400. doi: 10.1183/13993003.00400-2019. Print 2019 Mar. No abstract available.

PMID:
30886028
19.

Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis.

Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A.

Respir Res. 2019 Mar 1;20(1):47. doi: 10.1186/s12931-019-1010-5.

20.

Quantitative CT-derived vessel metrics in idiopathic pulmonary fibrosis: A structure-function study.

Jacob J, Pienn M, Payer C, Urschler M, Kokosi M, Devaraj A, Wells AU, Olschewski H.

Respirology. 2019 May;24(5):445-452. doi: 10.1111/resp.13485. Epub 2019 Feb 20.

21.

Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy.

Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciucchi S, Puglisi S, Mascetti S, Arcadu A, Tomassetti S, Poletti V.

Multidiscip Respir Med. 2019 Feb 8;14:3. doi: 10.1186/s40248-019-0170-y. eCollection 2019.

22.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Feb 14;53(2). pii: 1801939. doi: 10.1183/13993003.01939-2018. Print 2019 Feb. No abstract available.

PMID:
30765483
23.

Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality.

Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A.

Chest. 2019 May;155(5):972-981. doi: 10.1016/j.chest.2019.01.019. Epub 2019 Feb 8.

PMID:
30742809
24.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

PMID:
30665517
25.

Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients.

Ravaglia C, Wells AU, Tomassetti S, Gurioli C, Gurioli C, Dubini A, Cavazza A, Colby TV, Piciucchi S, Puglisi S, Bosi M, Poletti V.

BMC Pulm Med. 2019 Jan 16;19(1):16. doi: 10.1186/s12890-019-0780-3.

26.

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.

Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180076. doi: 10.1183/16000617.0076-2018. Print 2018 Dec 31. Review.

27.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

28.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2019 Apr;155(4):712-719. doi: 10.1016/j.chest.2018.11.008. Epub 2018 Nov 22.

29.

Pirfenidone improves survival in IPF: results from a real-life study.

Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, Antoniou KM.

BMC Pulm Med. 2018 Nov 23;18(1):177. doi: 10.1186/s12890-018-0736-z.

30.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

PMID:
30442715
31.

Variable radiological lung nodule evaluation leads to divergent management recommendations.

Nair A, Bartlett EC, Walsh SLF, Wells AU, Navani N, Hardavella G, Bhalla S, Calandriello L, Devaraj A, Goo JM, Klein JS, MacMahon H, Schaefer-Prokop CM, Seo JB, Sverzellati N, Desai SR; Lung Nodule Evaluation Group; Lung Nodule Evaluation Group.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801359. doi: 10.1183/13993003.01359-2018. Print 2018 Dec.

PMID:
30409817
32.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

33.

Sarcoidosis: A benign disease or a culture of neglect?

Wells AU.

Respir Med. 2018 Nov;144S:S1-S2. doi: 10.1016/j.rmed.2018.10.004. Epub 2018 Oct 6. No abstract available.

PMID:
30336997
34.

Author Correction: Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Nov;14(11):682. doi: 10.1038/s41584-018-0108-3.

PMID:
30317249
35.

Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution.

Wells AU.

Lancet Respir Med. 2019 Jan;7(1):7-8. doi: 10.1016/S2213-2600(18)30385-0. Epub 2018 Sep 14. No abstract available.

PMID:
30224324
36.

IPF diagnosis: flexibility is a virtue.

Wells AU.

Lancet Respir Med. 2018 Oct;6(10):735-737. doi: 10.1016/S2213-2600(18)30374-6. Epub 2018 Sep 14. No abstract available. Erratum in: Lancet Respir Med. 2018 Oct;6(10):e53.

PMID:
30224321
37.

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.

PMID:
30220235
38.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

39.

The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients.

Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T, Tomioka H, Taguchi Y, Nagai S, Chin K, Mishima M, Wells AU, Hirai T.

Respiration. 2018;96(4):338-347. doi: 10.1159/000490355. Epub 2018 Aug 21.

PMID:
30130749
40.

Major lung complications of systemic sclerosis.

Denton CP, Wells AU, Coghlan JG.

Nat Rev Rheumatol. 2018 Sep;14(9):511-527. doi: 10.1038/s41584-018-0062-0. Review. Erratum in: Nat Rev Rheumatol. 2018 Nov;14(11):682.

PMID:
30111804
41.

Sarcoidosis: is cryobiopsy not cool enough? - Authors' reply.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 Sep;6(9):e45. doi: 10.1016/S2213-2600(18)30217-0. Epub 2018 Jul 11. No abstract available.

PMID:
30007850
42.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

43.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Kouranos V, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Nathan SD.

Respir Med. 2018 Jun;139:72-78. doi: 10.1016/j.rmed.2018.04.015. Epub 2018 May 5.

PMID:
29858005
44.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May. Review.

PMID:
29773608
45.

Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis.

Jacob J, Odink A, Brun AL, Macaluso C, de Lauretis A, Kokosi M, Devaraj A, Desai S, Renzoni E, Wells AU.

Respir Med. 2018 May;138:95-101. doi: 10.1016/j.rmed.2018.03.031. Epub 2018 Mar 30.

46.

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.

Behr J, Nathan SD, Harari S, Wuyts W, Kirchgaessler KU, Bengus M, Gilberg F, Wells AU.

Respir Med. 2018 May;138:13-20. doi: 10.1016/j.rmed.2018.03.019. Epub 2018 Mar 16.

47.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

48.

Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.

Kokosi MA, Margaritopoulos GA, Wells AU.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 170117. doi: 10.1183/16000617.0117-2017. Print 2018 Jun 30. Review.

49.

Pulmonary sarcoidosis.

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU.

Lancet Respir Med. 2018 May;6(5):389-402. doi: 10.1016/S2213-2600(18)30064-X. Epub 2018 Apr 3. Review.

PMID:
29625772
50.

Rapidly Progressive Cystic Lung Disease.

Rogers C, Kent-Bramer J, Devaraj A, Nicholson AG, Molyneaux PL, Wells AU, Saikia S, Maher TM, George PM.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):264. doi: 10.1164/rccm.201801-0161IM. No abstract available.

Supplemental Content

Loading ...
Support Center